Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Directors Deals Ltd.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Stryker Corp Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates; Reaffirms FY 2013 EPS Gudiance-Conference Call


Wednesday, 23 Jan 2013 09:30pm EST 

Stryker Corp announced that for fiscal 2013, it expects sales growth, excluding foreign exchange and acquisitions, of 3% to 5.5%, with adjusted diluted net earnings per share (EPS) of $4.25 to $4.40, up 4% to 8%, which includes the roughly $100 million pretax impact from the medical device excise tax. The Company reported revenue of $8.657 billion in fiscal 2012. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $8.96 billion and EPS of $4.31 for fiscal 2013. 

Company Quote

91.9
0.5 +0.55%
25 Nov 2014